Skip to main content

Genomics and genome-editing inquiry


The previous Committee reported on Advanced Genetic techniques for crop improvement: regulation, risk and precaution in February 2015. At the beginning of 2016, the Committee included GM and gene editing in its 'evidence check' process. Genomics England is working towards sequencing 100,000 whole human genomes by the end of 2017, supported by 13 Genomic Medicine Centres. In September 2016 the Nuffield Council on Bioethics published an ethical review on genome editing, looking at the potential issues across human health, food production, wildlife and the ecosystem. The Parliamentary Office for Science and Technology (POST) recently published a POSTnote on genome editing which looks at current and future uses of genome editing, how it is regulated and potential concerns.

Against that background, the Committee has decided to undertake an inquiry into genomics and genome-editing.

Reports, special reports and government responses

View all reports and responses
16th Report - Genomics and genome-editing: future lines of inquiry
Inquiry Genomics and genome-editing inquiry
HC 854

Oral evidence transcripts

View all oral evidence transcripts
29 March 2017
Inquiry Genomics and genome-editing inquiry
Witnesses Professor Waseem Qasim, Professor of Cell and Gene Therapy, Institute of Child Health, Alastair Kent, Director, Genetic Alliance UK, and Dr Kathy Niakan, Group Leader, Francis Crick Institute; Dr Andy Greenfield, Programme Leader, Medical Research Council's Harwell Institute, Robin Lovell-Badge, Senior Group Leader, Francis Crick Institute, James Lawford Davies, Partner, Hempsons, and Philippa Taylor, Head of Public Policy, Christian Medical Fellowship
Oral Evidence
8 March 2017
Inquiry Genomics and genome-editing inquiry
Witnesses Dr Edward Hockings, Founder, Ethics and Genetics, Professor Michael Parker, Director, Ethox Centre, University of Oxford, and Non-executive Director and Chair, Ethics Advisory Committee, Genomics England, Peter Counter, Chief Information Officer and Project Manager, Genomics England, and Alison Hall, Head of Humanities, PHG Foundation; Professor Sir Mike Stratton, Director, Wellcome Trust Sanger Institute, and Chief Executive Officer, Wellcome Genome Campus, and Dr Jean Abraham, Academic Honorary Consultant in Medical Oncology, University of Cambridge
Oral Evidence
8 February 2017
Inquiry Genomics and genome-editing inquiry
Witnesses Professor Sue Hill, Chief Scientific Officer, NHS England, Professor Mark Caulfield, Chief Scientist, Genomics England, and Dr Julia Wilson, Associate Director, Wellcome Trust Sanger Institute; Professor Sir John Burn, Non-executive Director, NHS England, Professor Dame Kay Davies, Non-executive Director, Genomics England, and Dr Helen Firth, Clinical Lead, Deciphering Developmental Disorders Project, Wellcome Trust Sanger Institute
Oral Evidence
The Association of Cancer Physicians (GEN0064)
University of Cambridge and Cancer Research UK Cambridge Centre (GEN0063)
British Society for Genetic Medicine (GEN0062)

Other publications

No other publications published.

Contact us

We can’t usually help you with an individual problem or a specific complaint.

  • Email:
  • Phone: 020 7219 5023 (general enquiries) | 020 7219 4984 (media enquiries)
  • Address: Science, Innovation and Technology Committee, House of Commons, London, SW1A 0AA